Zosano Pharma Corporation (NASDAQ:ZSAN) Director Kenneth Greathouse acquired 50,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was bought at an average price of $0.62 per share, for a total transaction of $31,000.00. Following the acquisition, the director now owns 35,000 shares of the company’s stock, valued at approximately $21,700. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Zosano Pharma Corporation (ZSAN) traded up $0.03 during trading on Thursday, reaching $0.65. The company’s stock had a trading volume of 499,728 shares, compared to its average volume of 1,563,556. Zosano Pharma Corporation has a fifty-two week low of $0.54 and a fifty-two week high of $3.54.
Zosano Pharma Corporation (NASDAQ:ZSAN) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.05). equities research analysts anticipate that Zosano Pharma Corporation will post -0.79 earnings per share for the current year.
Separately, ValuEngine upgraded Zosano Pharma Corporation from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.
A hedge fund recently raised its stake in Zosano Pharma Corporation stock. Northern Trust Corp raised its position in shares of Zosano Pharma Corporation (NASDAQ:ZSAN) by 591.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 79,234 shares of the biotechnology company’s stock after acquiring an additional 67,774 shares during the quarter. Northern Trust Corp owned approximately 0.20% of Zosano Pharma Corporation worth $112,000 at the end of the most recent quarter. 22.67% of the stock is owned by institutional investors and hedge funds.
About Zosano Pharma Corporation
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.